Leerink Swann Reiterates “Market Perform” Rating for ACADIA Pharmaceuticals Inc. (ACAD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)‘s stock had its “market perform” rating restated by stock analysts at Leerink Swann in a research report issued to clients and investors on Monday.

ACAD has been the topic of a number of other research reports. ValuEngine upgraded ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 10th. Zacks Investment Research lowered ACADIA Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub upgraded ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 5th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $46.00 price target (up previously from $42.00) on shares of ACADIA Pharmaceuticals in a research report on Thursday, August 10th. Six equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $46.21.

ACADIA Pharmaceuticals (ACAD) opened at 36.91 on Monday. The firm’s market capitalization is $4.52 billion. The firm’s 50-day moving average price is $36.35 and its 200 day moving average price is $31.67. ACADIA Pharmaceuticals has a 1-year low of $20.68 and a 1-year high of $41.20.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.17. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. The firm had revenue of $30.50 million for the quarter, compared to analyst estimates of $20.02 million. During the same quarter in the previous year, the company posted ($0.63) EPS. The business’s revenue was up 30400.0% on a year-over-year basis. On average, analysts predict that ACADIA Pharmaceuticals will post ($2.53) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/10/11/leerink-swann-reiterates-market-perform-rating-for-acadia-pharmaceuticals-inc-acad.html.

In related news, EVP Glenn Baity sold 37,500 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $40.91, for a total transaction of $1,534,125.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 116,426 shares of company stock worth $4,100,885. 22.25% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the stock. Utah Retirement Systems raised its stake in ACADIA Pharmaceuticals by 1.1% during the 2nd quarter. Utah Retirement Systems now owns 17,600 shares of the biopharmaceutical company’s stock worth $491,000 after buying an additional 200 shares during the period. Stifel Financial Corp raised its stake in ACADIA Pharmaceuticals by 3.1% during the 1st quarter. Stifel Financial Corp now owns 8,708 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 260 shares during the period. Oppenheimer Asset Management Inc. raised its stake in ACADIA Pharmaceuticals by 10.0% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 5,133 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 468 shares during the period. Principal Financial Group Inc. raised its stake in ACADIA Pharmaceuticals by 3.6% during the 2nd quarter. Principal Financial Group Inc. now owns 16,810 shares of the biopharmaceutical company’s stock worth $469,000 after buying an additional 579 shares during the period. Finally, Tocqueville Asset Management L.P. raised its stake in ACADIA Pharmaceuticals by 0.6% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 100,560 shares of the biopharmaceutical company’s stock worth $2,805,000 after buying an additional 610 shares during the period. 97.10% of the stock is currently owned by institutional investors and hedge funds.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Analyst Recommendations for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply